{"nctId":"NCT00436553","briefTitle":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","startDateStruct":{"date":"2007-02"},"conditions":["Macular Degeneration","Choroidal Neovascularization"],"count":321,"armGroups":[{"label":"Verteporfin With Standard Fluence Rate Plus Ranibizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Verteporfin Photodynamic Therapy","Drug: Ranibizumab","Drug: Ranibizumab Placebo"]},{"label":"Ranibizumab Monotherapy","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Ranibizumab","Drug: Verteporfin Placebo"]},{"label":"Verteporfin With Reduced Fluence Rate Plus Ranibizumab","type":"EXPERIMENTAL","interventionNames":["Drug: Verteporfin Photodynamic Therapy","Drug: Ranibizumab","Drug: Ranibizumab Placebo"]}],"interventions":[{"name":"Verteporfin Photodynamic Therapy","otherNames":["Visudyne"]},{"name":"Ranibizumab","otherNames":["Lucentis"]},{"name":"Verteporfin Placebo","otherNames":[]},{"name":"Ranibizumab Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects of either gender age 50 years or older\n* Subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD)\n\nExclusion Criteria:\n\n* Choroidal neovascularization due to causes other than AMD\n* Prior treatment for neovascular AMD in the study eye\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12","description":"BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increase in the VA score indicates improvement in visual acuity.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.7","spread":"13.52"},{"groupId":"OG001","value":"54.6","spread":"12.78"},{"groupId":"OG002","value":"54.8","spread":"13.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.0","spread":"17.47"},{"groupId":"OG001","value":"59.0","spread":"18.03"},{"groupId":"OG002","value":"63.0","spread":"18.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.3","spread":"15.66"},{"groupId":"OG001","value":"4.4","spread":"15.47"},{"groupId":"OG002","value":"8.1","spread":"15.09"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Total Area of Leakage of the Study Eye at Month 12","description":"Total area of leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.654","spread":"4.0956"},{"groupId":"OG001","value":"6.211","spread":"5.0618"},{"groupId":"OG002","value":"6.931","spread":"4.6473"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.472","spread":"4.2340"},{"groupId":"OG001","value":"3.024","spread":"4.0188"},{"groupId":"OG002","value":"3.177","spread":"4.9930"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.182","spread":"4.9729"},{"groupId":"OG001","value":"-3.187","spread":"5.9744"},{"groupId":"OG002","value":"-3.753","spread":"5.8005"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With Fluorescein Leakage in the Study Eye at Month 12","description":"The percentage of patients with leakage of the study eye was assessed at the Central Reading Center (CRC) using Fluorescein angiography (FA).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.2","spread":"0"},{"groupId":"OG001","value":"54.5","spread":"0"},{"groupId":"OG002","value":"41.8","spread":"0"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Central Retinal Thickness at Month 12","description":"Optical coherence tomography was performed in the study eyes and the evaluations of the images were performed by the central reading center.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"444.654","spread":"137.7119"},{"groupId":"OG001","value":"446.638","spread":"129.5482"},{"groupId":"OG002","value":"456.824","spread":"153.4270"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"292.921","spread":"79.2733"},{"groupId":"OG001","value":"305.719","spread":"80.4508"},{"groupId":"OG002","value":"284.586","spread":"75.4892"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-151.733","spread":"135.6200"},{"groupId":"OG001","value":"-140.919","spread":"128.0741"},{"groupId":"OG002","value":"-172.238","spread":"166.6691"}]}]}]},{"type":"PRIMARY","title":"Percent of Patients With a Treatment-free Interval of at Least 3 Months Following the Month 2 Visit","description":"The number of patients with a ranibizumab treatment-free interval, ie, no active ranibizumab treatments for at least 3 months duration (at least 2 consecutive monthly visits), anytime following the Month 2 ranibizumab treatment. Only active ranibizumab treatments were considered.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.6","spread":null},{"groupId":"OG001","value":"83.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":32,"n":104},"commonTop":["Eye pain (Study eye)","Conjunctival haemorrhage (Study eye)","Hypertension","Nasopharyngitis","Upper respiratory tract infection"]}}}